WuXi NextCODE Genomics, the newly formed genomic analysis division of WuXi PharmaTech, led a $15 million Series B financing in Claritas Genomics. Claritas is a Boston-based lab that develops and provides next-gen sequence-based tests for pediatric genomic disorders. The company was spun out of Boston Children’s Hospital two years ago with assistance from Life Technologies. WuXi NextCODE was formed earlier this year when WuXi PharmaTech paid $65 million to acquire NextCODE Health, a genomics sequencing company.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
